Genetic-Guided Oral P2Y12 Inhibitor Selection and Cumulative Ischemic Events After Percutaneous Coronary Intervention
Primary result · Cumulative ischemic events (LOF carriers)Result — go to the resultHazard ratio 0.61 95% CI 0.41–0.89Authors' conclusion
Among CYP2C19 LOF carriers undergoing PCI, a genetic-guided strategy resulted in a statistically significant reduction in cumulative ischemic events without a significant difference in bleeding.
Study context
- Population
- Post-PCI patients with acute or stable coronary artery disease (CAD); analysis in CYP2C19 loss-of-function (LOF) carriers1,849 LOF carriers
- Participants
- 5,276 patients
- Comparison
- Genetic-guided vs Conventional therapy
- Genetic-guidedn = 903
- Conventional therapyn = 946reference
- Primary endpoint
- Cumulative incidence rate of ischemic events
- Follow-up
- 12 months
Methodological detailscumulative endpoints (Wei, Lin, and Weissfeld Cox models)
- Cumulative endpoints (Wei, Lin, and Weissfeld Cox models)
Primary result
Cumulative ischemic events (LOF carriers)
Hazard ratio
0.61
95% CI 0.41–0.89
P = 0.011
Genetic-guided vs Conventional therapy
HR 0.61 (95% CI 0.41–0.89); P = 0.011
As reported in the abstract
Safety
| Outcome | HR (95% CI) | P value | |
|---|---|---|---|
| Cumulative major or minor bleeding | 1.36 (0.67–2.76) | P = 0.39 | |
| 0.20.5125Hazard ratio (log scale) |
Original publication
Genetic-Guided Oral P2Y12 Inhibitor Selection and Cumulative Ischemic Events After Percutaneous Coronary Intervention. JACC Cardiovasc Interv. Published 10 April 2023. doi:10.
Summarised from the published abstract; every number is checked against it